Testing tumor blood-type markers in relapsed lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks for tumor “signatures” (including tiny RNA molecules, or miRNA) to predict outcomes in people with relapsed or resistant diffuse large B‑cell lymphoma (DLBCL). Your tissue samples help researchers see which patients may benefit from standard chemotherapy plus antibody treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (age over 18).
- You have diffuse large B‑cell lymphoma (DLBCL) that has come back (relapsed) or is resistant.
- You can receive the study’s planned first-line and/or salvage chemo-immunotherapy (standard cancer medicines).
- You have at least one visible disease spot on a scan (bigger than 1.5 cm at its longest point).
- You can provide tumor tissue samples (fresh and FFPE/archived biopsy tissue) for testing.
- You do not have other serious active cancers or health problems that would interfere with chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This trial uses a blood test to look for tumor DNA in people with high-risk B-cell lymphoma, to help predict if the lymphoma might spread to the brain or spinal cord. It may help doctors decide on extra treatments to prevent that spread.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study uses special lab testing (“omics”) on people with certain fast-growing B-cell lymphomas to find results that can help with diagnosis and predicting outcomes. It may help by improving how clinicians identify the lymphoma type and forecast how it may behave.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
This Phase 2 trial tests a PD-1 antibody (anti–PD-1) added to standard R-CHOP chemotherapy for certain people with diffuse large B-cell lymphoma (DLBCL) who have a p53 mutation and tumor PD-L1 expression. It may help shrink lymphoma more effectively when these tumor markers are present.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.